Skip to main content

Investor RelationsWealth Management:  CA  |  UK  |  AU

Menu
BCTG Acquisition Corp.

Canaccord Genuity Acts as Financial Advisor to BCTG Acquisition Corp. on Merger with Tango Therapeutics

Canaccord Genuity is pleased to announce that on April 14, 2021, Tango Therapeutics, a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, and BCTG Acquisition Corp. (Nasdaq: BCTG), a special purpose acquisition company (SPAC) sponsored by Boxer Capital have entered into a definitive merger agreement. Upon closing of the transaction, the company will be named Tango Therapeutics, Inc. (Combined Company).

Current Tango shareholders are converting 100% of their existing equity interests into common stock of the Combined Company. In addition to the approximately $167 million held in the BCTG trust account (less any redemptions), an additional group of premier healthcare investors has committed to participate in the transaction through a common stock PIPE of approximately $186 million at $10.00 per share.

The Combined Company is expected to receive gross proceeds of approximately $353 million at the closing of the transaction.

More like this

ChartWise Medical Systems, Inc.
June 2021

ChartWise Medical Systems, Inc.

Financial Advisor to ChartWise Medical Systems, Inc. on its sale to Iodine Software, a portfolio company of Silversmith Capital Partners and Bain Capital Ventures
View transaction detail
Susquehanna Growth Equity
May 2021

Susquehanna Growth Equity

Financial Advisor to Susquehanna Growth Equity on its Majority Investment in MediSpend
MediSpend logo
View transaction detail
Trulieve
US$2.1b
May 2021

Trulieve

Financial Advisor to Trulieve on its acquisition of Harvest Health & Recreation Inc.